[ad_1]
The minister’s spokeswoman, Lina Bušinskaitė, informed BNS about it on Monday.
According to her, the vice minister is currently feeling poor, has had a certificate of disability for some time, so he is not at work.
The Health Ministry said, among other things, that it would cooperate with law enforcement agencies and would provide all the necessary information to complete the investigation as soon as possible.
L. Bušinskaitė stated that he was unable to comment on the ongoing investigation, but added that he hoped that the case would not prevent health workers from continuing to cooperate in managing the coronavirus outbreak.
“All colleagues, including the Deputy Minister, worked day and night, sparing no effort on weekends to control the spread of the virus in the country alone,” said L. Bušinskaitė.
According to the FNTT, the study is suspected that the Vice Minister for the Purchase of Rapid Tests of Rapid Coronavirus worth EUR 1 billion is possible office abuse, misuse of powers, which could have caused significant damage to the state.
The return measure for L. Jaruševičienė is a written promise not to leave. In total, six people have already been charged in this pre-trial investigation.
The investigation was reported in early June, with officials in sight: 6 million. Acquisition of rapid coronavirus tests by the National Public Health Laboratory for a value of EUR 1 000 000.
According to FNTT, the pre-trial investigation started after receiving information on suspected financial transactions from a company registered in Lithuania.
According to BNS, officials are investigating the activities of Profarma, the company that provided the evidence.
The funds the company tried to eliminate were obtained after a public acquisition contract with the National Laboratory of Public Health for the sale of COVID-19 rapid tests. According to the FNTT, the disposition of illegally obtained funds is restricted.
According to the study, which amounts to 6 million. The company allegedly falsified the documents and provided the buyer with false information about the manufacturer of the rapid tests for COVID-19.
The buyer is suspected of possibly being misled by failing to conduct a market investigation and failing to assess the price and market conditions of the purchased goods prior to concluding the contract. After concluding the contract, the funds were transferred to the test provider.
[ad_2]
